Listen to Susan O’Brien, MD, professor of medicine, and Catherine C. Coombs, MD, associate professor of medicine, both of the Chao Family Comprehensive Cancer Center at the University of California, Irvine, on the SOHO Insider podcast.
They discuss frontline chronic lymphocytic leukemia (CLL) treatments from the EHA 2025 meeting in Milan along with the AMPLIIFY trial, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024.
The GAIA/CLL13 trial showed venetoclax-based options, such as venetoclax plus obinutuzumab or a triplet with ibrutinib, outperforming chemoimmunotherapy, particularly for mutated IGHV patients. “…the patients who had the best outcomes were the patients who received venetoclax plus obinutuzumab, … with or without ibrutinib” Dr. Coombs said.
The AMPLIFY trial, presented at ASH, tested fixed duration acalabrutinib plus venetoclax, with or without obinutuzumab, for young, fit CLL patients. Drs. O’Brien and Dr. Coombs also share how therapies are being chosen based on patient needs, balancing potency, and convenience.
